>
Switch to:

Biohaven Pharmaceutical Holding Co Debt-to-Equity

: -0.69 (As of Dec. 2020)
View and export this data going back to 2017. Start your Free Trial

Biohaven Pharmaceutical Holding Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $0.00 Mil. Biohaven Pharmaceutical Holding Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $267.46 Mil. Biohaven Pharmaceutical Holding Co's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $-390.37 Mil. Biohaven Pharmaceutical Holding Co's debt to equity for the quarter that ended in Dec. 2020 was -0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

NYSE:BHVN' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.69   Med: -0.11   Max: 0
Current: -0.69

-0.69
0
NYSE:BHVN's Debt-to-Equity is ranked higher than
94% of the 1071 Companies
in the Biotechnology industry.

( Industry Median: 0.08 vs. NYSE:BHVN: -0.69 )

Biohaven Pharmaceutical Holding Co Debt-to-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-Equity Premium Member Only -0.11 0.00 0.00 0.00 -0.69

Biohaven Pharmaceutical Holding Co Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.24 -0.69

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Biohaven Pharmaceutical Holding Co Debt-to-Equity Distribution

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Debt-to-Equity falls into.



Biohaven Pharmaceutical Holding Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biohaven Pharmaceutical Holding Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Biohaven Pharmaceutical Holding Co's Debt to Equity Ratio for the quarter that ended in Dec. 2020 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Biohaven Pharmaceutical Holding Co Debt-to-Equity Related Terms


Biohaven Pharmaceutical Holding Co Debt-to-Equity Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)